Journal
CELLULAR & MOLECULAR IMMUNOLOGY
Volume 5, Issue 3, Pages 171-182Publisher
CHINESE SOC IMMUNOLOGY
DOI: 10.1038/cmi.2008.21
Keywords
MHC-I; TCR; MHC-I/TCR interaction; immune therapy
Categories
Ask authors/readers for more resources
Adoptive immunotherapy involving the transfer of autologous tumor or virus-reactive T lymphocytes has been demonstrated to be effective. in the eradication of cancer and virally infected cells. Identification of MHC-restricted antigens and progress in generation of adaptive immune responses have provided new direction for such treatment for severe pathologies such as cancer and autoimmune diseases. Here we review the latest development about the molecular basis of MHC-I/TCR interaction, and it's manipulation including enhanced MHC-I expression, modification of peptide and engineered TCR for clinical applications such as vaccine design, tumor therapy and autoimmune diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available